Untitled Document
Autoantibodies against cell nuclei (ANA)

ANA by IIFT

IMMUCARE use ANA Mosaic 20A (HEp-20-10 cells, primate liver, SS-A+SS-B BIOCHIPs, rib. P-prot.+Jo-1 BIOCHIPs): antibodies against SS-A/SS-B.

  • Screening test for the detection of antibodies against cell nuclei (ANA).
  • Indications: rheumatic diseases.
  • Using HEp-20-10 cells many antibodies against cell nuclei can be analysed, e.g. antibodies against DNA, histones, RNA, nRNP, Sm, SS-A, SS-B, nuclear dots, centromeres, nuclear membrane, nucleoli (PM-Scl, fibrillarin, RNA polymerase I, NOR), Scl-70, cyclin I and II, spindle fibers, midbody, centrioles.
  • In addition, cytoplasmic autoantibodies are identified with HEp-20-10 cells: antibodies against ribosomes, Jo-1, mitochondria, Golgi apparatus, actin etc.
  • The primate liver permits the verification of results between both substrates, makes the predifferentiation of a large number of ANA possible, and helps to establish titer levels. Moreover, the primate liver contains additional antigens, allowing the identification of further autoantibodies: antibodies against LMA, LSP, endomysium, bile ducts and endothelium cells, as well as cANCA and pANCA.
  • ANA Mosaic 20A system is a monospecific test that can be used to confirm the presence of autoantibodies against cell nuclei and cytoplasm components.

Innovative cell line HEp-20-10 with a high number of mitotic cells.

HEp-2010: antibodies against spindle fibers.

  • Screening test for detection of antibodies against cell nuclei.
  • Indications: rheumatic diseases.
  • Compared to conventional HEp-2 cells, HEp20-10 cells contain ten times as many mitotic cells. Antibodies against mitosis-specific structures (centromeres, spindle fibres, separation zone, centrioles, NOR) can be more easily identified than with conventional preparations.
  • At the same time the cell line HEp-20-10 offers the full antigen spectrum for the detection of cell nuclear antibodies.
  • We offers an innovative and high-performance automation solution for the evaluation of ANA in immunofluorescence.

ANA by ELISA

ANA Screen, Anti-ENA

ANA Screen ELISA (antigen mixture of dsDNA, histones, nRNP/Sm, Sm, SS-A, SS-B, Scl-70, Jo-1, ribosomal P-proteins, centromeres)

  • Screening test for predifferentiation of antibodies against cell nuclei (ANA) and cytoplasm components.
  • Indications: Sharp syndrome (MCTD), systemic lupus erythematosus, Sjögren's syndrome, progressive systemic sclerosis, polymyositis/dermatomyositis.
  • The ANA Screen ELISA supplements the gold standard immunofluorescence. It is based on a mixture of 10 highly purified antigens, which provide higher sensitivity and specificity.
  • Two ELISAs with different antigen combinations, adapted to particular indications or for follow-up of immunofluorescence patterns, are available.

Anti-ENA SLE Profile 2,Anti-ENA ProfilePlus 1/2

Anti-ENA ProfilePlus 2 ELISA (antigens: ribosomal P-proteins, nRNP/Sm, Sm, SS-A, SS-B, Scl-70, Jo-1, centromeres)

  • Differentiation of antibodies against cell nuclei (ANA) and cytoplasm components.
  • Indications: Sharp syndrome (MCTD), systemic lupus erythematosus, Sjögren's syndrome, progressive systemic sclerosis, polymyositis/dermatomyositis.
  • In total, 4 different ELISAs with different antigen combinations, adapted to particular indications or for follow-up of immunofluorescence patterns.

Monospecific ELISA with single antigens

Anti-SS-A ELISA

  • Differentiation of antibodies against cell nuclei (ANA) and cytoplasm components.
  • Indications: rheumatic diseases.
  • Antibodies against cell nuclei components can be determined quantitatively in RU/ml.
  • Single-antigen ELISAs available for detection of antibodies against cell nuclei and cytoplasm antigens: ssDNA, nucleosomes, dsDNA, histones, ribosomal P proteins, PM-Scl, nRNP/Sm, Sm, SS-A, SS-B, Scl-70, Jo-1, centromere.

IMMUNOBLOT

ANA Profile

ANA Profile

  • Differentiation of antibodies against cell nuclei (ANA).
  • Indications: Sharp syndrome (MCTD), systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, poly/dermatomyositis, PBC.
  • With the IMMUCARE ANA Profile , fifteen autoantibodies can be determined: antibodies against nRNP/Sm, Sm, SS-A, Ro-52, SS-B, Scl-70, PM-Scl, Jo-1, centromere protein B, PCNA, dsDNA, nucleosomes, histones, ribosomal P-proteins, AMA M2.
  • Antibodies against SS-A are characteristic markers for SLE and Sjögren’s syndrome. In contrast, antibodies against Ro-52 also occur in patients with other autoimmune diseases.

Autoimmune Inflammatory Myopathies 16 Ag

  • Differentiation of myositis-associated antibodies against cell-nuclear and cytoplasmic antigens.
  • Indications: poly/dermatomyositis.
  • With IMMUCARE Autoimmune Inflammatory Myopathies 16 Ag, 16 autoantibodies can be determined: antibodies against Mi-2 alpha, Mi-2 beta, TIF1g, MDA5, NXP2, SAE1, Ku, PM-Scl100, PM-Scl75, Jo-1, SRP, PL-7, PL-12, EJ, OJ, Ro-52.

Systemic Sclerosis (Nucleoli) Profile

  • Differentiation of systemic sclerosis-associated antibodies against cell-nuclear antigens.
  • Indications: systemic sclerosis (SSc, diffuse and limited form), overlap syn¬dromes.
  • With IMMUCARE Systemic Sclerosis Profile (Nucleoli), thirteen autoantibodies can be determined: anti¬bodies against Scl-70, CENP A, CENP B, RP11 (RNAP-III), RP155 (RNAP-III), fibrillarin, NOR-90, Th/To, PM-Scl100, PM-Scl75, Ku, PDGFR, Ro-52.

WB HEp-2 Cell Antigens plus SS-A, Ro-52 and CENP B

WB HEp-2 Cell Antigens plus SS-A, Ro-52 and CENP B

  • Differentiation of antibodies against cell-nuclear and cytoplasmic antigens.
  • Indications: Sharp syndrome (MCTD), systemic lupus erythematosus, Sjögren’s syndrome, progressive systemic sclerosis, poly/dermatomyositis, PBC.
  • IMMUCARE WB is a combination of westernblot and line blot techniques.
  • Antibodies against SS-A are characteristic markers for SLE and Sjögren’s syndrome. In contrast, antibodies against Ro-52 also occur in patients with other autoimmune diseases. IMMUCARE WB contains both antigens next to each other at defined positions, in addition to the complete HEp-2 antigen spectrum of the Westernblot. The use of native SS-A increases the sensitivity, since 37% of antibodies against SS-A do not show any reaction with the denatured antigen from the Westernblot

Technical info and Images credit to EUROIMMUN AG